Interval breast cancer risk associations with breast density, family history and breast tissue aging.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 07 2020
Historique:
received: 29 07 2019
revised: 16 09 2019
accepted: 27 09 2019
pubmed: 15 10 2019
medline: 9 3 2021
entrez: 15 10 2019
Statut: ppublish

Résumé

Interval breast cancers (those diagnosed between recommended mammography screens) generally have poorer outcomes and are more common among women with dense breasts. We aimed to develop a risk model for interval breast cancer. We conducted a nested case-control study within the Melbourne Collaborative Cohort Study involving 168 interval breast cancer patients and 498 matched control subjects. We measured breast density using the CUMULUS software. We recorded first-degree family history by questionnaire, measured body mass index (BMI) and calculated age-adjusted breast tissue aging, a novel measure of exposure to estrogen and progesterone based on the Pike model. We fitted conditional logistic regression to estimate odds ratio (OR) or odds ratio per adjusted standard deviation (OPERA) and calculated the area under the receiver operating characteristic curve (AUC). The stronger risk associations were for unadjusted percent breast density (OPERA = 1.99; AUC = 0.66), more so after adjusting for age and BMI (OPERA = 2.26; AUC = 0.70), and for family history (OR = 2.70; AUC = 0.56). When the latter two factors and their multiplicative interactions with age-adjusted breast tissue aging (p = 0.01 and 0.02, respectively) were fitted, the AUC was 0.73 (95% CI 0.69-0.77), equivalent to a ninefold interquartile risk ratio. In summary, compared with using dense breasts alone, risk discrimination for interval breast cancers could be doubled by instead using breast density, BMI, family history and hormonal exposure. This would also give women with dense breasts, and their physicians, more information about the major consequence of having dense breasts-an increased risk of developing an interval breast cancer.

Identifiants

pubmed: 31609476
doi: 10.1002/ijc.32731
pmc: PMC7318124
doi:

Substances chimiques

Estrogens 0
Progesterone 4G7DS2Q64Y

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

375-382

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Références

Int J Epidemiol. 2017 Apr 1;46(2):652-661
pubmed: 28338721
Radiology. 2018 Feb;286(2):433-442
pubmed: 29040039
Ann Oncol. 2015 Mar;26(3):517-22
pubmed: 25488685
Radiographics. 1998 Nov-Dec;18(6):1587-98
pubmed: 9821201
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Tumori. 2010 Mar-Apr;96(2):198-201
pubmed: 20572574
Am J Epidemiol. 2014 Feb 15;179(4):475-83
pubmed: 24169466
Ann Intern Med. 2015 May 19;162(10):673-81
pubmed: 25984843
Br J Cancer. 2003 Sep 1;89(5):852-9
pubmed: 12942117
Ann Intern Med. 2016 Nov 15;165(10):700-712
pubmed: 27548583
Breast Cancer Res. 2016 Jun 18;18(1):63
pubmed: 27316945
Breast Cancer Res. 2015 Nov 18;17:142
pubmed: 26581435
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65
pubmed: 26677205
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Am J Epidemiol. 1994 Apr 15;139(8):819-35
pubmed: 8178795
J Clin Oncol. 2015 Mar 20;33(9):1030-7
pubmed: 25646195
Breast Cancer Res. 2018 Dec 13;20(1):152
pubmed: 30545395
NPJ Breast Cancer. 2017 Apr 13;3:12
pubmed: 28649652
JAMA Oncol. 2018 Jul 1;4(7):998-1001
pubmed: 29801067
J Am Coll Radiol. 2019 Feb;16(2):139-146
pubmed: 30287178
Breast Cancer Res. 2013 Jun 20;15(3):R48
pubmed: 23786804
J Am Coll Radiol. 2016 Nov;13(11S):R53-R57
pubmed: 27814815
Breast Cancer Res Treat. 2018 Jul;170(1):129-141
pubmed: 29502324
Asia Pac J Clin Nutr. 1994 Mar;3(1):19-31
pubmed: 24351203
J Am Coll Radiol. 2013 Dec;10(12):899-902
pubmed: 24295937
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130475
JNCI Cancer Spectr. 2018 Dec 07;2(4):pky057
pubmed: 31360877
Nature. 1983 Jun 30;303(5920):767-70
pubmed: 6866078
Am J Epidemiol. 2015 Nov 15;182(10):863-7
pubmed: 26520360
N Engl J Med. 2015 Jun 11;372(24):2353-8
pubmed: 26039523
IARC Sci Publ. 2002;156:69-70
pubmed: 12484128
J Natl Cancer Inst. 2019 Jun 1;111(6):629-632
pubmed: 30624682
J Natl Cancer Inst. 2014 Sep 12;106(10):
pubmed: 25217577

Auteurs

Tuong L Nguyen (TL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Shuai Li (S)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Gillian S Dite (GS)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Ye K Aung (YK)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Christopher F Evans (CF)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Ho N Trinh (HN)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Laura Baglietto (L)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Jennifer Stone (J)

Centre for Genetic Origins of Health and Disease, University of Western Australia, Perth, WA, Australia.

Yun-Mi Song (YM)

Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Joohon Sung (J)

Department of Epidemiology School of Public Health, Seoul National University, Seoul, South Korea.
Institute of Health and Environment, Seoul National University, Seoul, South Korea.

Dallas R English (DR)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.

Mark A Jenkins (MA)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Pierre-Antoine Dugué (PA)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.

Roger L Milne (RL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.

Melissa C Southey (MC)

Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.

Graham G Giles (GG)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.

Malcolm C Pike (MC)

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.

John L Hopper (JL)

Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH